... FDA Approval of Tecvayli Plus Darzalex Faspro for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line — Johnson & Johnson ...
... Gains FDA Orphan Drug Designation in R/R Multiple Myeloma — Targeted Oncology Dual BCMA/CD19 CAR T-Cell Therapy AZD0120 Shows Promise for Multiple Myeloma — OncLive Management of Adverse Reactions for BCMA-Directed Therapy in Relapsed Multiple Myeloma: A Focused Review — Journal of Clinical Medicine Abecma — Drugs.com Carvykti Side Effects — Drugs.com Tecvayli ...
What Is BCMA-Targeted Immunotherapy? (VIDEO)
... Gains FDA Orphan Drug Designation in R/R Multiple Myeloma — Targeted Oncology Dual BCMA/CD19 CAR T-Cell Therapy AZD0120 Shows Promise for Multiple Myeloma — OncLive Management of Adverse Reactions for BCMA-Directed Therapy in Relapsed Multiple Myeloma: A Focused Review — Journal of Clinical Medicine Abecma — Drugs.com Carvykti Side Effects — Drugs.com Tecvayli ...
... Multiple Myeloma — Cancers The BiTE (Bispecific T-Cell Engager) Platform: Development and Future Potential of a Targeted Immuno-Oncology Therapy Across Tumor Types — Cancer Emerging Bispecific T-Cell Engagers in Myeloma: Promises and Hurdles — Pharmacy Times Refractory and Relapsed — Leukemia & Lymphoma Society Highlights of Prescribing Information: Tecvayli ...
Bispecific T-Cell Engagers for RRMM: 6 Facts About a New Type of Treatment
... Multiple Myeloma — Cancers The BiTE (Bispecific T-Cell Engager) Platform: Development and Future Potential of a Targeted Immuno-Oncology Therapy Across Tumor Types — Cancer Emerging Bispecific T-Cell Engagers in Myeloma: Promises and Hurdles — Pharmacy Times Refractory and Relapsed — Leukemia & Lymphoma Society Highlights of Prescribing Information: Tecvayli ...
... Examples include elranatamab (Elrexfio), teclistamab (Tecvayli), talquetamab (Talvey), and linvoseltamab-gcpt (Lynozyfic). Nuclear export inhibitors — These drugs block XPO1, a protein that helps cancer cells survive. Selinexor (Xpovio) is the first FDA-approved XPO1 inhibitor, preventing this process and causing cancer cell death. ...
Can Multiple Myeloma Be Cured? Advances in Research and Survival
... Examples include elranatamab (Elrexfio), teclistamab (Tecvayli), talquetamab (Talvey), and linvoseltamab-gcpt (Lynozyfic). Nuclear export inhibitors — These drugs block XPO1, a protein that helps cancer cells survive. Selinexor (Xpovio) is the first FDA-approved XPO1 inhibitor, preventing this process and causing cancer cell death. ...
... options for RRMM include: Immunotherapy with chimeric antigen receptor T-cell therapy using such options as idecabtagene vicleucel (Abecma) and ciltacabtagene autoleucel (Carvykti) Proteasome inhibitors like bortezomib, carfilzomib (Kyprolis), and ixazomib (Ninlaro) IMiDs like pomalidomide (Pomalyst) Bispecific T-cell engagers like teclistamab-cqyv (Tecvayli ...
What Is the Life Expectancy With Relapsed/Refractory Myeloma?
... options for RRMM include: Immunotherapy with chimeric antigen receptor T-cell therapy using such options as idecabtagene vicleucel (Abecma) and ciltacabtagene autoleucel (Carvykti) Proteasome inhibitors like bortezomib, carfilzomib (Kyprolis), and ixazomib (Ninlaro) IMiDs like pomalidomide (Pomalyst) Bispecific T-cell engagers like teclistamab-cqyv (Tecvayli ...
... Teclistamab-cqyv (Tecvayli) is the first bispecific antibody that targets both the protein B-cell maturation antigen (BCMA) and CD3 (a protein on T cells). This helps bring T cells directly to the cancer cells to kill them. Linvoseltamab-gcpt (Lynozyfic) is a newer BCMA-directed T-cell engager. ...
Relapsed vs. Refractory: What It Means in Multiple Myeloma
... Teclistamab-cqyv (Tecvayli) is the first bispecific antibody that targets both the protein B-cell maturation antigen (BCMA) and CD3 (a protein on T cells). This helps bring T cells directly to the cancer cells to kill them. Linvoseltamab-gcpt (Lynozyfic) is a newer BCMA-directed T-cell engager. ...
... These treatments can also cause CRS and other side effects, so close monitoring is necessary during the first few doses.Bispecific antibodies used to treat myeloma include: Elranatamab-bcmm (Elrexfio) Linvoseltamab-gcpt (Lynozyfic) Talquetamab-tgvs (Talvey) Teclistamab-cqyv (Tecvayli) Antibody-Drug ConjugateAnother immunotherapy your doctor may recommend ...
Myeloma Treatment Journey: From First Line to Fourth Line
... These treatments can also cause CRS and other side effects, so close monitoring is necessary during the first few doses.Bispecific antibodies used to treat myeloma include: Elranatamab-bcmm (Elrexfio) Linvoseltamab-gcpt (Lynozyfic) Talquetamab-tgvs (Talvey) Teclistamab-cqyv (Tecvayli) Antibody-Drug ConjugateAnother immunotherapy your doctor may recommend ...
... , approved in 2022) — have emerged as options for individuals with relapsed or refractory multiple myeloma.In 2019, the FDA approved selinexor (Xpovio), offering a new mechanism of action as a selective inhibitor of nuclear export.The approval of isatuximab-irfc (Sarclisa) in 2020, along with newer bispecific T-cell engagers like teclistamab-cqyv (Tecvayli ...
Multiple Myeloma – An Overview
... , approved in 2022) — have emerged as options for individuals with relapsed or refractory multiple myeloma.In 2019, the FDA approved selinexor (Xpovio), offering a new mechanism of action as a selective inhibitor of nuclear export.The approval of isatuximab-irfc (Sarclisa) in 2020, along with newer bispecific T-cell engagers like teclistamab-cqyv (Tecvayli ...
... Teclistamab-cqyv (Tecvayli) was approved in 2022 to treat people with multiple myeloma who have previously received four or more lines of therapy. Teclistamab-cqyv is the first BiTE to be indicated for myeloma. ...
... As of July 2025, four bispecific antibodies — elranatamab-bcmm (Elrexfio), talquetamab (Talvey), teclistamab-cqyv (Tecvayli), and linvoseltamab-gcpt (Lynozyfic) — have been approved for myeloma. ...
Myeloma Treatments: Risks and Benefits
... As of July 2025, four bispecific antibodies — elranatamab-bcmm (Elrexfio), talquetamab (Talvey), teclistamab-cqyv (Tecvayli), and linvoseltamab-gcpt (Lynozyfic) — have been approved for myeloma. ...
Join
